Pfizer Research Center

Pfizer Research Center

Chris Ratcliffe/Bloomberg

Teva Pharmaceutical Industries Ltd., Mylan Inc., and Lupin Ltd. were among the generic-drug makers who successfully argued that New York-based Pfizer Inc.’s patent wasn’t different enough from the one expiring in May.